Atherosclerosis
Volume 209, Issue 1 , Pages 1-9 , March 2010

Lipid transfer proteins: Past, present and perspectives

Received 26 May 2009 ,Revised 2 July 2009 ,Accepted 3 August 2009.

References 

  1. Lepper PM, Schumann C, Triantafilou K, et al. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol. 2007;50(1):25–31
  2. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(12):2227–2236
  3. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50(suppl.):S201–S206
  4. Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from gram-negative bacterial membranes. Infect Immun. 2000;68(5):2410–2417
  5. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J Biol Chem. 1996;271(May (21)):12172–12178
  6. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180(3):1025–1035
  7. Barlage S, Fröhlich D, Böttcher A, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res. 2001;42(2):281–290
  8. Vuletic S, Taylor BA, Tofler GH, et al. PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction. Oral Dis. 2008;14(6):514–519
  9. Gautier T, Klein A, Deckert V, et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. J Biol Chem. 2008;283(27):18702–18710
  10. Cazita PM, Barbeiro DF, Moretti AIS, Quintão ECR, Soriano FG. CETP expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30(5):590–595
  11. Cazita PM, Salerno AG, Ferreira FD, Nunes VS, Oliveira KS, Soriano FG, et al. Abstract 5539: human CETP expression promotes the plasma clearance and hepatic uptake of lipopolysaccharide. Circulation. 2008;118:(S_570b)
  12. Stein O, Stein Y. Lipid transfer proteins (LTP) and athrerosclerosis. Atherosclerosis. 2005;178(2):217–230
  13. Jiang XC, Zhou HW. Plasma lipid transfer proteins. Curr Opin Lipidol. 2006;17(3):302–308
  14. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev. 2009;10(4):403–411
  15. Magkos F, Mohammed BS, Mittendorfer B. Plasma lipid transfer enzymes in non-diabetic lean and obese men and women. Lipids. 2009;44(5):459–464
  16. Yamashita S, Sakai N, Hirano K, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Front Biosci. 2001;6:D366–D387
  17. Silver DL, Jiang XC, Arai T, Bruce C, Tall AR. Receptors and lipid transfer proteins in HDL metabolism. Ann N Y Acad Sci. 2000;902:103–111
  18. O’Brien KD, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 2003;108(3):270–274
  19. Schlitt A, Blankenberg S, Bickel C, et al. Phospholipid transfer protein activity is a risk factor for subsequent cardiovascular events in coronary artery disease patients under statin therapy: the atherogene study. J Lipid Res. 2009;50(4):723–729
  20. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23(10):1857–1862
  21. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BH, van Tol A, Dullaart RP. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia. 2006;49(2):398–404
  22. Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis. 2005;178(2):365–370
  23. Schgoer W, Mueller T, Jauhiainen M, et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 2008;196(1):219–226
  24. Yatsuya H, Tamakoshi K, Hattori H, et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J. 2004;68(1):11–16
  25. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299(23):2777–2788
  26. Tsai MY, Johnson C, Kao WH, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200(2):359–367
  27. Hiura Y, Shen CS, Kokubo Y, Okamura T, Morisaki T, Tomoike H, et al. Identification of genetic markers associated with high-density lipoprotein-cholesterol by genome-wide screening in a Japanese population. Circ J. 2009;73(6):1119–1126
  28. Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J. 2008;29(22):2792–2799
  29. Pussinen PJ, Metso J, Malle E, et al. The role of plasma phospholipid transfer protein (PLTP) in HDL remodeling in acute-phase patients. Biochim Biophys Acta. 2001;28(2):153–163
  30. Van Haperen R, Samyn H, Moerland M, et al. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS ONE. 2008;3(5):e2255
  31. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2(9):504–511
  32. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18(4):427–434
  33. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta. 2005;1733(2–3):187–191
  34. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res. 2004;45(10):1852–1858
  35. Jiang XC, Tall AR, Qin S, et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem. 2002;277(35):31850–31856
  36. Lie J, de Crom R, van Gent T, et al. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res. 2004;45(5):805–811
  37. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol. 2003;23(9):1601–1607
  38. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK. Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J Lipid Res. 2008;49(1):24–32
  39. Kosuge M, Ebina T, Ishikawa T, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J. 2007;71(2):186–190
  40. Yang RZ, Lee MJ, Hu H, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006;3(6):e287
  41. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 1993;364(6432):73–75
  42. Masucci-Magoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals changes in plasma cholesterol levels. J Clin Invest. 1996;97(1):154–161
  43. Zhou H, Li Z, Hojjati MR, et al. Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. J Lipid Res. 2006;47(9):2011–2019
  44. Bruce C, Chouinard RA, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998;18:297–330
  45. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26(11):2552–2559
  46. de Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, Rensen PC. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis. 2009 Mar 19. [Epub ahead of print].
  47. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem. 1995;64:235–257
  48. Tsutsumi K, Hagi A, Inoue Y. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol Pharm Bull. 2001;24(5):579–581
  49. Casquero AC, Berti JA, Salerno AG, et al. Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice. J Lipid Res. 2006;47(7):1526–1534
  50. Cazita PM, Berti JA, Aoki C, et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res. 2003;44(1):33–40
  51. Kako Y, Massé M, Huang LS, Tall AR, Goldberg IJ. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res. 2002;43(6):872–877
  52. Hayek T, Masucci-Magoulas L, Jiang X, et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96(4):2071–2074
  53. Hayek T, Azrolan N, Verdery RB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice. J Clin Invest. 1993;92(3):1143–1152
  54. Föger B, Chase M, Amar MJ, et al. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem. 1999;274(52):36912–36920
  55. Harder C, Lau P, Meng A, Whitman SC, McPherson R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(4):858–864
  56. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol. 2005;25(10):2177–2184
  57. Rotllan N, Calpe-Berdiel L, Guillaumet-Adkins A, Süren-Castillo S, Blanco-Vaca F, Escolà-Gil JC. CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Atherosclerosis. 2008;196(2):505–513
  58. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 2007;116(11):1267–1273
  59. Harada LM, Amigo L, Cazita PM, et al. CETP expression enhances liver HDL-Cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis. 2007;191:313–318
  60. Rocco D, Catanozi S, Okuda L, et al. Aerobic exercise training improves the in vitro macrophage reverse cholesterol transport in wild type and in huCETPTG mice. In: Worshop III-1. Abstract 509. XV International Congress on Atherosclerosis. Boston. MA, USA, June 14–18.. 2009;
  61. Moerland M, Samyn H, van Gent T, et al. Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(7):1277–1282
  62. van Haperen R, van Tol A, van Gent T, et al. Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem. 2002;277(50):48938–48943
  63. Lie J, Moerland M, van Gent T, et al. Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides. Biochim Biophys Acta. 2006;1761(9):1070–1077
  64. Samyn H, Moerland M, van Gent T, et al. Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study. J Lipid Res. 2008;49(12):2504–2512
  65. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(1):190–196
  66. Valenta DT, Ogier N, Bradshaw G, et al. Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol. 2006;26(7):1572–1578
  67. Vikstedt R, Ye D, Metso J, et al. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol. 2007;27(3):578–586
  68. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001;7(7):847–852
  69. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels J. Clin Invest. 1999;103(6):907–914
  70. Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta. 1999;1439(1):65–76
  71. Samyn H, Moerland M, van Gent T, et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009;204(2):429–434
  72. Cheung MC, Brown BG, Marino Larsen EK, Frutkin AD, O’Brien KD, Albers JJ. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta. 2006;1762(1):131–137
  73. Bossé Y, Bouchard L, Després JP, Bouchard C, Pérusse L, Vohl MC. Haplotypes in the phospholipid transfer protein gene are associated with obesity-related phenotypes: the Québec Family Study. Int J Obes (Lond). 2005;29(11):1338–1345
  74. Pussinen PJ, Malle E, Metso J, Sattler W, Raynes JG, Jauhiainen M. Acute-phase HDL in phospholipid transfer protein (PLTP)-mediated HDL conversion. Atherosclerosis. 2001;155(2):297–305
  75. Levels JH, Pajkrt D, Schultz M, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta. 2007;1771(12):1429–1438
  76. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119(8):1135–1145
  77. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005;25(5):1057–1064
  78. Kee P, Caiazza D, Rye KA, Barrett PH, Morehouse LA, Barter PJ. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscler Thromb Vasc Biol. 2006;26(4):884–890
  79. Tchoua U, D'Souza W, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res. 2008;77(4):732–739
  80. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by Torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J Lipid Res. 2007;48(6):1263–1267
  81. de Haan W, de Vries-van der Weij J, van der Hoorn JW, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 2008;117(19):2515–2522
  82. Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122(the ILLUMINATE investigators)
  83. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor Torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008;118(24):2515–2522
  84. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CEPT inhibition and HDL elevation). Circulation. 2008;118(24):2506–2514
  85. Nissen SE, Tardif JC, Nicholls SJ, et al. ILLUSTRATE Investigators. Effect of Torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–1316
  86. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of Torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356(16):1620–1630
  87. Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by Torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27(5):1132–1138
  88. Catalano G, Julia Z, Frisdal E, et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol. 2009;29(2):268–275
  89. Hardardóttir I, Moser AH, Fuller J, Fielding C, Feingold K, Grünfeld C. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in syrian hamsters. J Clin Invest. 1996;97(11):2585–2592
  90. Chien JY, Jerng JS, Yu CJ, Yang PC. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med. 2005;33(8):1688–1693
  91. Jahangiri A, de Beer MC, Noffsinger V, et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol. 2009;29(2):261–267
  92. Deguchi H, Fernández JA, Griffin JH. Plasma cholesteryl ester transfer protein and blood coagulability. Thromb Haemost. 2007;98(6):1160–1164

PII: S0021-9150(09)00627-3

doi: 10.1016/j.atherosclerosis.2009.08.002

Atherosclerosis
Volume 209, Issue 1 , Pages 1-9 , March 2010

Article Tools

* Image Usage & Resolution